The Therapeutic Goods Administration (TGA) has issued a critical reminder regarding the use of FluMist, an intranasal influenza vaccine, emphasizing the importance of adhering to its age indications. This update comes in the wake of a concerning incident where over 80 children received the vaccine in May, despite it not being approved for their age group.
A Misstep in Vaccine Administration
The TGA's alert highlights a significant issue: FluMist is specifically indicated for children and adolescents aged between two and 17 years. The recent reports of adverse events involving children under two years of age have raised red flags. The Department of Health, Disability, and Ageing reported that 116 out of 161 FluMist-related adverse event reports in May 2026 were linked to children under two, with 89 instances of the vaccine being administered to patients of inappropriate age and 38 cases of the wrong product being given.
While none of these incidents were deemed serious, the potential risks cannot be overlooked. The government has advised healthcare professionals to be vigilant and double-check the age of the child before administering FluMist. This simple yet crucial step can prevent unnecessary exposure to the vaccine's potential side effects.
FluMist's Reach and Funding
FluMist is funded for specific age groups in different states. In Queensland and New South Wales, it is available for all children aged between two and 17 years. Western Australia covers children between two and 12 years, while South Australia focuses on those aged two to five. Interestingly, the vaccine is also available via private prescription for other children in Western and South Australia, as well as for those aged two to 17 in Victoria, the Northern Territory, and Tasmania.
The SNIFFLES Study and Its Implications
The Murdoch Children’s Research Institute's SNIFFLES study is an intriguing development. It allows children aged two to nine to receive FluMist instead of the standard injectable flu shot. This study raises questions about the effectiveness and safety of FluMist in younger age groups, which could have significant implications for future vaccine recommendations.
Influenza's Impact and Surveillance
The National Notifiable Disease Surveillance System has recorded a staggering 34,799 cases of laboratory-confirmed influenza between January 1 and June 10. Over 4300 of these cases occurred in children under five years of age. These statistics underscore the importance of proper vaccine administration and the need to understand the nuances of each vaccine's indications.
A Call for Awareness and Education
The TGA's update serves as a stark reminder of the importance of adhering to vaccine guidelines. It highlights the need for healthcare professionals to stay informed and for parents to be aware of the appropriate age ranges for different vaccines. As the flu season progresses, ensuring that vaccines are administered correctly will be crucial in maintaining public health.
